Research Article - Biomedical Research (2017) Volume 28, Issue 22
Influences analysis of lenalidomide on multiple myeloma, inflammatory factor, regulatory T cell and T-lymphocyte subsets
Objective: To explore influences of lenalidomide on multiple myeloma, inflammatory factor, regulatory T cell and T-lymphocyte subsets.
Methods: 176 Multiple Myeloma (MM) patients in our hospital from April, 2013 to April, 2013 were divided into the observation group and the control group. The control group was given VAD treatment. The observation group was given lenalidomide and dexamethasone. One month was one course. The treatment gives 5 courses. M protein, β2-microglobulin level, HGB, BMPC in serum before and after treatment were detected and analysed and given effective rate statistics for patients according to indexes above. Changes of immune function relevant inflammatory factor of IL-6, TNF-α concentration, regulatory T cell (Tregs), T-lymphocyte subsets, CD4+T cell, CD8+T cell, Natural Killer cell (NK) percentage in vivo before and after treatment in two groups were detected and analysed.
Results: After 5 courses’ analysis, the effective rate in the observation group was 79.5% (70/88) which higher than 68.2% in the control group (60/88). Before treatment, there is not significant differences (P>0.05) in M protein, β2-microglobulin, bone marrow plasma cell and haemoglobin of both groups. However, after the treatment, the M protein, β2-microglobulin, bone marrow plasma cell and haemoglobin are (15.29 ± 5.29 g/L), (8.03 ± 0.039 mg/L), (6.09 ± 0.099%) and (99.21 ± 9.21 g/L), respectively, in the observation group, but (20.37 ± 0.37 g/L), (10.04 ± 0.04 mg/L), (13.09 ± 3.09%) and (80.67 ± 0.67 g/L), respectively, in the control group. M protein, β2-microglobulin level, BMPC all decreased greatly after treatment in the observation group, the increased level of HGB all higher than the control group, and there were significant differences in data between two groups after treatment (P<0.05). before treatment, IL-6, tumor necrosis factor, regulatory T cell percentage and T-lymphocyte subsets (CD4+T cell, CD8+T cell, NK) of both groups are not different significantly (P>0.05), after treatment, the testing results of the observation group are (1.3 ± 0.3 pg/ml), (0.8 ± 0.8 pg/ml), (1.09 ±0.09l %), (43.89 ± 3.89%), (27.48 ± 7.48%) and (13.98 ± 3.98%), respectively, while the results of the control group are (2.3 ± 0.3 sets pg/ml), (1.5 ± 0.5 m pg/ml), (2.21 ± 0.21l%), (37.67 ± 7.67%), (34.88 ± 4.88%) and (16.47 ± 6.47%), respectively. The decreased level of two inflammatory factors of IL-6, concentration of tumor necrosis factor, regulatory T cell percentage, CD8+T cell in T-lymphocyte subsets, NK percentage in vivo in the observation group all higher than the control group, the increased level of CD4+T cell percentage and CD8+T cell percentage all higher than the control group, and there were significant differences in data between two groups after treatment (P<0.05).
Conclusion: After lenalidomide in treating MM, the clinical effects are well. Immune function improves better, it shows the clinical value of lenalidomide is high.Author(s): Li Lijuan, Li Yuming, Zhang Liansheng